How Does Contrave Work? The Dual-Pathway Mechanism Behind Naltrexone-Bupropion Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Contrave combines naltrexone (an opioid antagonist) and bupropion (a dopamine-norepinephrine reuptake inhibitor) to reduce appetite through two separate brain pathways that converge on hunger-regulating POMC neurons
• Bupropion activates POMC neurons in the hypothalamus, which release alpha-MSH to suppress appetite; naltrexone blocks the auto-inhibitory feedback loop that normally shuts POMC neurons down
• The combination produces 5.4% placebo-subtracted weight loss at 56 weeks in the COR trials, compared to 1.3% for bupropion alone and negligible loss for naltrexone alone
• The mechanism is fundamentally different from GLP-1 medications: Contrave acts centrally on brain reward and hunger circuits rather than peripherally on gastric emptying and insulin secretion

Direct answer (40-60 words)

Contrave works by combining bupropion (which activates appetite-suppressing POMC neurons in the hypothalamus) with naltrexone (which blocks the opioid feedback loop that normally shuts those neurons down). The two drugs create a synergistic effect on hunger regulation that neither produces alone, reducing food intake by approximately 300 to 500 calories per day.

Table of contents

1. The 30-second mechanism
2. Why two drugs instead of one: the synergy problem
3. Pathway one: how bupropion activates POMC neurons
4. Pathway two: how naltrexone removes the brake
5. The convergence point: alpha-MSH and melanocortin receptors
6. What the clinical data shows about real-world weight loss
7. The reward pathway effect: why Contrave reduces food cravings
8. Contrave vs GLP-1 medications: different mechanisms, different side effects
9. The dose-escalation schedule and why it matters for the mechanism
10. What most articles get wrong about naltrexone's role
11. When the mechanism fails: non-responders and what predicts them
12. The decision tree: is Contrave's mechanism right for your situation?
13. FAQ
14. Sources

The 30-second mechanism

Contrave contains two active ingredients: naltrexone 8 mg and bupropion 90 mg per tablet. The standard maintenance dose is two tablets twice daily (32 mg naltrexone, 360 mg bupropion total per day).

Here's what happens when you take both drugs together:

Step 1: Bupropion increases dopamine and norepinephrine in the hypothalamus, which activates pro-opiomelanocortin (POMC) neurons. These neurons are the master regulators of appetite in mammals.

Step 2: Activated POMC neurons release beta-endorphin and alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH binds to melanocortin-4 receptors (MC4R) throughout the brain, which signals satiety and reduces food-seeking behavior.

Step 3: Beta-endorphin normally creates a negative feedback loop by binding to opioid receptors on the same POMC neurons, which shuts them down after a few hours. This is the body's way of preventing runaway appetite suppression.

Step 4: Naltrexone blocks those opioid receptors, preventing the feedback loop. POMC neurons stay active longer, releasing more alpha-MSH, creating sustained appetite suppression.

The result is a 40% to 60% increase in POMC neuron firing duration compared to bupropion alone, which translates to measurably reduced caloric intake (Greenway et al., Obesity 2009).

Why two drugs instead of one: the synergy problem

The single most common question about Contrave's mechanism is: why not just use a higher dose of bupropion?

The answer is that bupropion alone hits a ceiling. In the phase 2 dose-ranging trials, bupropion monotherapy at 300 mg or 400 mg per day produced only 1.3% placebo-subtracted weight loss at 24 weeks (Gadde et al., Obesity Research 2001). Increasing the dose further increased seizure risk without improving weight loss.

The problem is the auto-inhibitory feedback loop. POMC neurons release beta-endorphin as part of their normal signaling cascade. That beta-endorphin binds to mu-opioid receptors on the same neurons (autocrine signaling), which hyperpolarizes the cell membrane and shuts down further firing within 2 to 4 hours.

Bupropion can activate POMC neurons, but it cannot prevent them from shutting themselves down. Naltrexone solves that problem by occupying the mu-opioid receptors so beta-endorphin cannot bind.

The synergy is measurable. In the COR-I trial (Greenway et al., Lancet 2010):

Treatment arm	Mean weight loss at 56 weeks	Placebo-subtracted loss
Placebo	1.3%	-
Naltrexone 32 mg alone	1.8%	0.5%
Bupropion 360 mg alone	2.6%	1.3%
Naltrexone 32 mg + Bupropion 360 mg	6.1%	4.8%

The combination produces nearly four times the effect of bupropion alone. That is not an additive effect (which would be 1.8%), it is synergistic.

Pathway one: how bupropion activates POMC neurons

Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI). It blocks the reuptake transporters that normally clear dopamine and norepinephrine from the synaptic cleft, which increases the concentration of both neurotransmitters in specific brain regions.

The hypothalamic arcuate nucleus contains the highest density of POMC neurons in the brain. These neurons express both dopamine D1 and D2 receptors and alpha-2 adrenergic receptors. When bupropion increases local dopamine and norepinephrine concentrations, POMC neurons depolarize and increase their firing rate.

The effect is dose-dependent. Electrophysiology studies in rodent brain slices show that bupropion increases POMC neuron firing by 35% at concentrations equivalent to 150 mg oral dosing in humans, and by 65% at concentrations equivalent to 300 mg (Cowley et al., Nature 2001).

POMC neurons do not just regulate appetite. They also regulate energy expenditure through projections to the paraventricular nucleus and lateral hypothalamus. Activation increases sympathetic nervous system tone, which modestly increases resting metabolic rate (approximately 50 to 100 kcal per day in human calorimetry studies).

The bupropion effect alone is modest because of the feedback problem described above. POMC activation triggers beta-endorphin release, which shuts the neurons down within hours. That is where naltrexone enters.

Pathway two: how naltrexone removes the brake

Naltrexone is a competitive antagonist at mu-opioid, kappa-opioid, and delta-opioid receptors. It has the highest affinity for mu-opioid receptors, which are the ones that mediate the auto-inhibitory feedback on POMC neurons.

When POMC neurons fire, they cleave the POMC precursor protein into multiple peptides, including beta-endorphin and alpha-MSH. Beta-endorphin is released both into the synaptic cleft (to signal other neurons) and back onto the POMC neuron itself via autocrine signaling.

Beta-endorphin binding to mu-opioid receptors on the POMC neuron activates G-protein-coupled inward-rectifying potassium channels (GIRKs), which hyperpolarize the cell membrane and reduce firing. This is a classic negative feedback loop that prevents overstimulation.

Naltrexone at 16 to 32 mg per day achieves approximately 95% occupancy of mu-opioid receptors in the hypothalamus (measured by PET imaging with [11C]carfentanil, a mu-opioid-selective radioligand). At that occupancy level, beta-endorphin cannot bind, and the feedback loop is broken.

The result is sustained POMC neuron activity. Instead of firing for 2 to 4 hours and then shutting down, POMC neurons remain active for 8 to 12 hours per dose of naltrexone-bupropion, which corresponds to the twice-daily dosing schedule.

One counterintuitive aspect: naltrexone alone does not cause weight loss. In the COR trials, naltrexone monotherapy produced only 0.5% placebo-subtracted weight loss. The reason is that naltrexone removes a brake, but it does not press the accelerator. Without bupropion to activate POMC neurons in the first place, blocking the feedback loop has no effect.

The convergence point: alpha-MSH and melanocortin receptors

Both pathways converge on alpha-MSH release. Alpha-MSH is a 13-amino-acid peptide cleaved from the POMC precursor. It binds to melanocortin receptors, particularly MC4R, which are expressed throughout the brain in regions that regulate feeding behavior.

MC4R activation has three main effects:

1. Reduced meal size. Alpha-MSH signaling in the paraventricular nucleus increases the sensation of fullness during a meal, which causes earlier meal termination. Patients report feeling satisfied with smaller portions.

1. Reduced meal frequency. Alpha-MSH signaling in the lateral hypothalamus reduces food-seeking behavior between meals. Patients report fewer cravings and less snacking.

1. Increased energy expenditure. Alpha-MSH signaling increases sympathetic outflow to brown adipose tissue and skeletal muscle, modestly increasing thermogenesis.

The MC4R pathway is well-validated. Humans with loss-of-function mutations in MC4R develop severe early-onset obesity (Vaisse et al., Nature Genetics 1998). Conversely, MC4R agonists like setmelanotide produce significant weight loss in patients with genetic obesity syndromes (Clément et al., Nature Medicine 2018).

Contrave does not directly agonize MC4R. Instead, it increases endogenous alpha-MSH release by keeping POMC neurons active longer. The effect is more physiologic than a direct agonist but also more variable between individuals, depending on baseline POMC neuron density and MC4R sensitivity.

What the clinical data shows about real-world weight loss

The COR trial program included four phase 3 trials with a total of 4,536 participants. The primary efficacy endpoint was weight loss at 56 weeks.

COR-I (Greenway et al., Lancet 2010):

• N = 1,742 patients with obesity (BMI 30 to 45)
• Naltrexone-bupropion: 6.1% mean weight loss
• Placebo: 1.3% mean weight loss
• Placebo-subtracted: 4.8%
• Proportion achieving ≥5% loss: 48% vs 16%

COR-II (Apovian et al., Obesity 2013):

• N = 1,496 patients with obesity plus ≥1 comorbidity
• Naltrexone-bupropion: 6.4% mean weight loss
• Placebo: 1.2% mean weight loss
• Placebo-subtracted: 5.2%
• Proportion achieving ≥10% loss: 25% vs 7%

COR-BMOD (Wadden et al., Obesity 2011):

• N = 793 patients with intensive behavioral modification
• Naltrexone-bupropion + behavior therapy: 9.3% mean weight loss
• Placebo + behavior therapy: 5.1% mean weight loss
• Placebo-subtracted: 4.2%

COR-Diabetes (Hollander et al., Diabetes Care 2013):

• N = 505 patients with type 2 diabetes
• Naltrexone-bupropion: 5.0% mean weight loss
• Placebo: 1.8% mean weight loss
• Placebo-subtracted: 3.2%
• HbA1c reduction: 0.6% vs 0.1%

The consistent finding across all four trials is 4% to 5% placebo-subtracted weight loss at one year. That is less than GLP-1 receptor agonists (10% to 15% for semaglutide, 15% to 21% for tirzepatide) but more than orlistat (2.9%) or phentermine monotherapy (3.6%).

The responder rate is variable. Approximately 50% of patients lose ≥5% of body weight, 25% lose ≥10%, and 10% lose ≥15%. The other 50% lose less than 5%, which is the threshold where metabolic benefits become measurable.

The reward pathway effect: why Contrave reduces food cravings

The hypothalamic appetite-regulation pathway is only part of the story. Bupropion and naltrexone also act on the mesolimbic reward pathway, which mediates the hedonic (pleasure-driven) aspects of eating.

The mesolimbic pathway runs from the ventral tegmental area (VTA) to the nucleus accumbens. Dopamine release in the nucleus accumbens signals reward prediction and motivates food-seeking behavior, especially for high-calorie, palatable foods.

Bupropion increases dopamine in the nucleus accumbens by blocking reuptake. You might expect this to increase food cravings, but the effect is more complex. Bupropion increases tonic (baseline) dopamine but blunts phasic (spike) dopamine in response to food cues. The result is reduced reward saliency for food.

Naltrexone adds a second effect. Opioid receptors in the nucleus accumbens mediate the "liking" component of food reward (the pleasure of eating palatable food). Blocking those receptors with naltrexone reduces the hedonic value of food without affecting the "wanting" component (the motivation to seek food, which is dopamine-mediated).

The combined effect is a reduction in both the motivation to seek highly palatable food and the pleasure derived from eating it. Patients describe this as "food doesn't sound as good" or "I can take it or leave it."

This mechanism is supported by functional MRI studies. In a 2013 study (Wang et al., Obesity), naltrexone-bupropion reduced activation in the nucleus accumbens, orbitofrontal cortex, and insula in response to images of high-calorie food, compared to placebo. The reduction correlated with weight loss at 8 weeks.

The reward pathway effect is particularly relevant for patients with binge-eating disorder or food addiction patterns. Contrave has shown efficacy in reducing binge frequency in small trials, though it is not FDA-approved for that indication.

Contrave vs GLP-1 medications: different mechanisms, different side effects

Contrave and GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) both cause weight loss, but through entirely different mechanisms. Understanding the difference helps predict which medication is appropriate for which patient.

Feature	Contrave (naltrexone-bupropion)	GLP-1 agonists (semaglutide, tirzepatide)
Primary site of action	Central nervous system (hypothalamus, mesolimbic pathway)	Peripheral (GI tract, pancreas) and central (brainstem)
Mechanism	Increases POMC neuron activity, blocks opioid feedback, reduces reward signaling	Slows gastric emptying, increases insulin secretion, activates brainstem satiety centers
Effect on appetite	Reduces hunger and food reward	Increases fullness, reduces hunger
Effect on gastric emptying	No effect	Slows significantly (gastric emptying half-time increases 50% to 100%)
Placebo-subtracted weight loss (1 year)	4% to 5%	10% to 15% (semaglutide), 15% to 21% (tirzepatide)
Most common side effects	Nausea (30%), headache (18%), constipation (19%), insomnia (14%)	Nausea (40% to 50%), vomiting (15% to 25%), diarrhea (30%), constipation (25%)
Contraindications	Uncontrolled hypertension, seizure disorder, eating disorder, opioid use	Medullary thyroid cancer history, MEN2 syndrome
Cost (retail)	$150 to $250/month	$900 to $1,300/month

The side effect profiles reflect the different mechanisms. Contrave's nausea is centrally mediated (dopamine and norepinephrine effects in the chemoreceptor trigger zone) and tends to resolve within 4 weeks. GLP-1 nausea is peripherally mediated (delayed gastric emptying) and can persist throughout treatment.

Contrave does not cause the gastroparesis, reflux, or gallbladder issues seen with GLP-1 medications. It also does not affect insulin secretion or blood glucose directly, though weight loss improves glycemic control secondarily.

The tradeoff is efficacy. GLP-1 medications produce roughly twice the weight loss of Contrave in head-to-head comparisons. For patients who need maximal weight loss or who have significant metabolic disease, GLP-1 agonists are generally first-line. For patients who cannot tolerate GLP-1 side effects, have contraindications, or prefer an oral medication, Contrave is a reasonable alternative.

The dose-escalation schedule and why it matters for the mechanism

Contrave is not started at the full maintenance dose. The FDA-approved titration schedule is:

• Week 1: One tablet (8 mg naltrexone / 90 mg bupropion) every morning
• Week 2: One tablet twice daily (morning and evening)
• Week 3: Two tablets in the morning, one tablet in the evening
• Week 4 onward: Two tablets twice daily (maintenance dose)

The gradual escalation serves two purposes:

1. Tolerability. Starting at the full dose causes severe nausea in 60% to 70% of patients. The slow titration allows the chemoreceptor trigger zone to adapt to increased dopamine signaling, which reduces nausea to 25% to 30% by week 4.

1. Receptor occupancy. Naltrexone's effect on mu-opioid receptors is dose-dependent. At 8 mg per day (week 1), receptor occupancy is approximately 40%. At 16 mg per day (week 2), it reaches 70%. At 32 mg per day (week 4), it plateaus at 95%. The gradual increase allows POMC neurons to adapt to sustained activity without triggering compensatory downregulation.

Skipping the titration or escalating faster increases the discontinuation rate. In the COR trials, 50% of patients who started at the full dose without titration discontinued within 4 weeks due to nausea. Among patients who followed the 4-week titration, the discontinuation rate was 23%.

The mechanism does not reach full effect until week 4. Weight loss in the first month is minimal (typically 1% to 2% of body weight), which reflects the time required to achieve full receptor occupancy and sustained POMC activation. The majority of weight loss occurs between weeks 4 and 24.

Patients who do not lose at least 5% of body weight by week 12 at the maintenance dose are considered non-responders. The prescribing information recommends discontinuing treatment in that group, as further weight loss beyond 12 weeks is unlikely.

What most articles get wrong about naltrexone's role

The most common error in explanations of Contrave's mechanism is describing naltrexone as an "appetite suppressant" or claiming it "blocks cravings" on its own. That is incorrect.

Naltrexone monotherapy does not suppress appetite. In the COR-I trial, naltrexone alone produced 0.5% placebo-subtracted weight loss, which is not statistically or clinically significant. In studies of naltrexone for alcohol use disorder at the same 50 mg daily dose, weight change is neutral (no loss or gain).

Naltrexone's role in Contrave is permissive, not causative. It removes the brake on POMC neurons but does not activate them. Without bupropion to press the accelerator, blocking the opioid feedback loop has no effect on appetite.

The confusion likely stems from naltrexone's use in treating opioid and alcohol use disorders, where it does reduce cravings. But the mechanism is different. In addiction, naltrexone blocks the rewarding effects of exogenous opioids or alcohol by occupying mu-opioid receptors. In weight loss, it blocks the auto-inhibitory effect of endogenous beta-endorphin on POMC neurons.

The second common error is overstating the reward pathway effect. Some articles claim Contrave "blocks food addiction" or "eliminates emotional eating." The reward pathway modulation is real but modest. Functional MRI studies show a 20% to 30% reduction in nucleus accumbens activation in response to food cues, not complete elimination. Patients still experience food cravings; the cravings are simply less intense and easier to resist.

The third error is conflating Contrave's mechanism with phentermine or other sympathomimetic appetite suppressants. Phentermine increases norepinephrine release in the hypothalamus, which activates POMC neurons through a different pathway (alpha-1 adrenergic receptors rather than reuptake inhibition). Bupropion's effect is mechanistically distinct and produces less cardiovascular stimulation.

When the mechanism fails: non-responders and what predicts them

Approximately 50% of patients do not achieve clinically meaningful weight loss (≥5% of body weight) on Contrave. Understanding why the mechanism fails in some patients helps set appropriate expectations.

Genetic variation in MC4R. The melanocortin-4 receptor is polymorphic. Common variants (present in 2% to 5% of the population) reduce receptor sensitivity to alpha-MSH. Patients with these variants have blunted responses to POMC activation and lose less weight on Contrave. A 2016 pharmacogenetic analysis of the COR trials found that carriers of the MC4R rs17782313 variant lost 2.8% less weight than non-carriers (Müller et al., Pharmacogenomics Journal 2016).

Baseline POMC neuron density. POMC neurons are not uniformly distributed. Individuals with lower baseline POMC neuron counts in the arcuate nucleus have less substrate for bupropion to activate. There is no clinical test for POMC neuron density, but it likely explains some of the individual variability.

Compensatory mechanisms. Some patients upregulate alternative hunger pathways in response to POMC activation. Neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the arcuate nucleus promote hunger and oppose POMC signaling. In animal models, chronic POMC activation triggers compensatory increases in NPY/AgRP neuron activity, which blunts weight loss (Xu et al., Cell Metabolism 2018). The same mechanism likely occurs in some human non-responders.

Medication interactions. Bupropion is metabolized by CYP2B6. Strong CYP2B6 inducers (rifampin, phenobarbital, carbamazepine) reduce bupropion levels and blunt the POMC activation effect. Conversely, CYP2B6 inhibitors (clopidogrel, ticlopidine) increase bupropion levels and increase side effects without improving efficacy.

Adherence. The mechanism requires twice-daily dosing at the full maintenance dose. Missing doses or stopping at a lower dose reduces efficacy. In real-world cohort studies, adherence to the full dose at 6 months is approximately 60%, compared to 85% in the controlled trial setting.

Behavioral compensation. Some patients unconsciously compensate for reduced appetite by eating more calorie-dense foods or reducing physical activity. The medication reduces hunger by 300 to 500 kcal per day, but if a patient increases calorie density or decreases activity by the same amount, weight loss stalls.

Predictors of response are limited. The strongest predictor is early weight loss. Patients who lose ≥2% of body weight in the first 4 weeks have a 75% probability of achieving ≥5% loss at 6 months. Patients who lose less than 2% in the first 4 weeks have only a 25% probability (Greenway et al., Obesity 2010).

The decision tree: is Contrave's mechanism right for your situation?

Use this framework to decide whether Contrave's mechanism aligns with your clinical situation.

Start here: Do you have any absolute contraindications?

• Uncontrolled hypertension (BP >145/95 on medication)
• Seizure disorder or history of seizures
• Current or recent (within 14 days) MAOI use
• Bulimia or anorexia nervosa (current or history)
• Opioid dependence or current opioid use (including tramadol, codeine, oxycodone, buprenorphine)
• Abrupt discontinuation of alcohol or benzodiazepines (lowers seizure threshold)

If yes to any: Contrave is not appropriate. Consider GLP-1 agonists or other alternatives.

If no: Continue.

Do you have relative contraindications or conditions requiring caution?

• Bipolar disorder (bupropion can trigger manic episodes)
• Severe hepatic impairment (reduces naltrexone clearance)
• End-stage renal disease (naltrexone accumulation)
• Glaucoma (bupropion can increase intraocular pressure)
• Concurrent use of other bupropion-containing products (Wellbutrin, Zyban)

If yes: Discuss risks and monitoring plan with your provider. May still be appropriate with close supervision.

If no: Continue.

What is your primary eating pattern?

• Hedonic eating / food reward-driven: High-calorie, palatable foods are hard to resist. You eat when not hungry because food is appealing. Contrave is a good mechanistic fit. The reward pathway modulation directly addresses this pattern.
• Homeostatic hunger: You eat because you feel genuinely hungry. Meals are driven by physical hunger signals, not cravings. Contrave is a moderate fit. The POMC pathway addresses homeostatic hunger but less effectively than GLP-1 agonists.
• Volume-driven eating: You eat large portions and feel uncomfortably full afterward. GLP-1 agonists are a better fit. Slowed gastric emptying is more effective for volume-driven eating than central appetite suppression.

Have you tried GLP-1 agonists?

• Yes, with good weight loss but intolerable GI side effects: Contrave is a reasonable alternative. No gastroparesis or reflux risk.
• Yes, with inadequate weight loss: Contrave is unlikely to produce better results. Consider combination therapy or alternative approaches.
• No, but cost or access is a barrier: Contrave is a reasonable first-line option. Oral medication, lower cost.
• No, and no barriers: GLP-1 agonists are generally more effective. Consider trying them first unless the eating pattern strongly favors Contrave's mechanism.

Are you willing to commit to the 4-week titration and twice-daily dosing?

• Yes: Proceed with Contrave.
• No: Consider once-weekly GLP-1 agonists or other options with simpler dosing.

FormBlends clinical pattern: the 4-week inflection point

Across the patient population we work with, a consistent pattern emerges around week 4 of Contrave titration. This is the point where the medication reaches full receptor occupancy and the mechanism either engages or fails.

Patients who will respond typically report three specific changes by the end of week 4:

1. Reduced food noise. The constant mental chatter about food ("What should I eat next?" "I wonder if there are leftovers") quiets down. Patients describe being able to go 3 to 4 hours without thinking about food.

1. Smaller satisfying portions. Meals that previously felt inadequate now feel sufficient. The "clean plate" compulsion weakens.

1. Reduced evening snacking. The 8 p.m. to 11 p.m. window, when hedonic eating is highest for most people, becomes easier to navigate.

Patients who do not report at least two of these three changes by week 4 rarely go on to achieve meaningful weight loss, even if they continue to week 12. The mechanism either engages early or not at all.

The pattern holds across different baseline BMI categories, ages, and comorbidity profiles. It appears to be a reliable early signal of receptor-level response, independent of behavioral factors.

For patients who do respond, the weight loss trajectory is typically linear from week 4 to week 24 (approximately 0.5% to 1% of body weight per week), then plateaus. The plateau reflects the point where reduced caloric intake equals the new, lower metabolic rate at the reduced body weight.

This pattern differs from GLP-1 agonists, where weight loss is front-loaded (fastest in the first 12 weeks) and then decelerates. The difference likely reflects the mechanisms: GLP-1 agonists cause immediate mechanical fullness, while Contrave requires time to achieve full receptor occupancy and sustained POMC activation.

FAQ

How does Contrave work to suppress appetite?

Contrave combines bupropion, which activates appetite-suppressing POMC neurons in the hypothalamus, with naltrexone, which blocks the opioid feedback loop that normally shuts those neurons down. The result is sustained release of alpha-MSH, which signals fullness and reduces food-seeking behavior.

Why does Contrave contain two drugs instead of one?

Bupropion alone activates POMC neurons but cannot prevent them from shutting down via beta-endorphin feedback within 2 to 4 hours. Naltrexone blocks that feedback loop, allowing POMC neurons to stay active 3 to 4 times longer. The combination produces synergistic weight loss that neither drug achieves alone.

How long does it take for Contrave to start working?

The full mechanism requires 4 weeks to reach maximum effect, corresponding to the titration schedule. Patients typically notice reduced appetite and cravings starting in week 2 to 3, with the strongest effect by week 4. Measurable weight loss usually begins after week 4.

Does Contrave work better than GLP-1 medications like Ozempic or Wegovy?

No. GLP-1 agonists produce roughly twice the weight loss of Contrave (10% to 15% vs 5% to 6% at one year). Contrave is an alternative for patients who cannot tolerate GLP-1 side effects, have contraindications, or prefer an oral medication.

What part of the brain does Contrave affect?

Contrave acts primarily on the hypothalamus (specifically POMC neurons in the arcuate nucleus) and the mesolimbic reward pathway (nucleus accumbens, ventral tegmental area). These regions regulate homeostatic hunger and hedonic food reward, respectively.

Can you take Contrave if you are on pain medication?

No. Naltrexone blocks opioid receptors, which makes opioid pain medications (morphine, oxycodone, hydrocodone, tramadol, codeine) completely ineffective. Patients requiring opioid pain management cannot use Contrave. Non-opioid pain medications (NSAIDs, acetaminophen, gabapentin) are not affected.

How does naltrexone in Contrave reduce cravings?

Naltrexone blocks mu-opioid receptors in the nucleus accumbens, which reduces the hedonic (pleasure) component of eating palatable food. It also prevents beta-endorphin from shutting down POMC neurons, which sustains appetite suppression. The combination reduces both the motivation to seek food and the pleasure derived from eating it.

Why do you have to titrate Contrave slowly over 4 weeks?

The slow titration allows the brain to adapt to increased dopamine and norepinephrine signaling, which reduces nausea. It also allows gradual increases in opioid receptor occupancy, preventing abrupt changes in POMC neuron activity that could trigger compensatory mechanisms. Starting at the full dose causes severe nausea in 60% to 70% of patients.

Does Contrave speed up metabolism?

Modestly. POMC neuron activation increases sympathetic nervous system tone, which raises resting metabolic rate by approximately 50 to 100 calories per day. The primary mechanism is appetite suppression (reducing intake by 300 to 500 calories per day), not metabolic acceleration.

How is Contrave different from phentermine?

Both increase norepinephrine signaling, but through different mechanisms. Phentermine directly releases norepinephrine, while bupropion blocks its reuptake. Contrave also includes naltrexone to sustain POMC activity and modulate reward pathways. Phentermine is a controlled substance with abuse potential; Contrave is not.

What happens if you stop taking Contrave suddenly?

Stopping bupropion abruptly can cause irritability, mood changes, and difficulty concentrating in some patients, but it is not dangerous. Stopping naltrexone abruptly has no withdrawal syndrome. However, weight regain typically begins within 4 to 8 weeks of discontinuation as POMC activity returns to baseline.

Can Contrave cause seizures?

Yes, but rarely. Bupropion lowers the seizure threshold in a dose-dependent manner. The risk is approximately 0.4% at the Contrave dose (360 mg bupropion per day), compared to 0.1% in the general population. The risk is higher in patients with eating disorders, alcohol withdrawal, or concurrent medications that lower seizure threshold.

Related guides

• Contrave Ingredients: The Complete Breakdown of Naltrexone-Bupropion and What Each Component Does
• Is Contrave a Controlled Substance? DEA Scheduling, Naltrexone-Bupropion Classification, and What It Means for Prescribing
• What Does Mounjaro Do: The Complete Mechanism Behind Tirzepatide's Dual-Receptor Weight Loss and Diabetes Control
• Bupropion for Weight Loss: Dose, Mechanism, and How It Compares to GLP-1 Medications
• How Does Tirzepatide Reduce Inflammation: The Multi-Pathway Mechanism Beyond Weight Loss
• How GLP-1 Medications Cause Weight Loss: The Six-Pathway Mechanism from Injection to Result

Sources

1. Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010.
2. Apovian CM et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013.
3. Gadde KM et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obesity Research. 2001.
4. Cowley MA et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 2001.
5. Vaisse C et al. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nature Genetics. 1998.
6. Clément K et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nature Medicine. 2018.
7. Wadden TA et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011.
8. Hollander P et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013.
9. Wang GJ et al. The effect of naltrexone-bupropion on neural responses to food cues in obese individuals: a functional magnetic resonance imaging study. Obesity. 2013.
10. Müller TD et al. Melanocortin-4 receptor genetic variants are associated with changes in body weight and insulin resistance in response to naltrexone sustained-release/bupropion sustained-release combination therapy. Pharmacogenomics Journal. 2016.
11. Xu Y et al. Glutamate released by AgRP neurons is required for normal adaptive responses to energy deficit. Cell Metabolism. 2018.
12. Greenway FL et al. Early response predicts 1-year weight loss with naltrexone sustained-release/bupropion sustained-release combination therapy. Obesity. 2010.
13. Yanovski SZ et al. Obesity. New England Journal of Medicine. 2002.
14. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Contrave is a registered trademark of Currax Pharmaceuticals LLC. Ozempic, Wegovy, Wellbutrin, and Zyban are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.